Molindone and Buprenorphine: Interaction Details

Brand names
Buprenorphine
ButransBelbucaSublocade +2 more
Molindone
Moban
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Buprenorphine

Brand names
  • Butrans
  • Belbuca
  • Sublocade
  • Buprenex
  • Brixadi

What Happens When You Take Molindone With Buprenorphine

What can happen when they are taken together (rated Major)

An increased risk of and

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Using buprenorphine together with a depressant can produce CNS depression, which raises the risk of respiratory depression, profound , coma, and death. Stopping the CNS depressant is favored over continuing both drugs.

Depending on the situation, it may be appropriate to monitor the patient in a higher level of care or to taper. In other situations, the better course may be to taper the patient gradually off a prescribed CNS depressant, or to lower it to the smallest effective dose.

When combined use cannot be avoided, monitor and manage the patient with caution, and consider alternative treatments for anxiety or insomnia.2 A Swedish epidemiological study found that patients on methadone- or buprenorphine-based medication-assisted treatment (MAT) who also took or other CNS depressants (for example, drugs used to treat insomnia) had a higher risk of death.

In an analysis of aggregate nationwide death certificate data from 2010 to 2014, most overdose deaths involving buprenorphine or methadone also involved the use of a CNS depressant. Whether the risk of overdose death with CNS depressants differed between buprenorphine and methadone is not known.1

The Molindone and Buprenorphine Interaction, Explained

Taking buprenorphine with molindone can make you much sleepier and slow your breathing. Buprenorphine is an used for pain or opioid use disorder. Molindone is an that can cause drowsiness. Both calm the brain, so together their effects add up. In serious cases this can lead to deep , trouble breathing, coma, or death.

Do not stop either medicine on your own. Your care team can manage this by choosing the lowest effective doses and watching you more closely. Tell them about any other sedating medicines, alcohol, or sleep aids you use. Get urgent help if you feel extremely drowsy or have slow or shallow breathing.

Mechanism: and () between buprenorphine (partial mu-opioid ) and molindone ( with sedative properties). Not a interaction, and no issue changes the direction. Effect: increased risk of respiratory depression, profound , coma, and death. Severity: major. Onset: unspecified. Evidence: probable (epidemiologic and overdose death data with CNS depressants as a class).

  • Cessation of the CNS depressant is preferred where feasible; consider taper or lowest effective dose.
  • If is necessary, monitor for sedation and respiratory depression; consider a higher level of care in some cases.
  • Consider alternatives for anxiety or insomnia.
  • Do not deny MAT to patients on CNS depressants; withholding it may carry greater morbidity and mortality.

See the 3 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Molindone and Buprenorphine Interact

The likely mechanism

In short: Molindone and buprenorphine both slow brain activity, so taken together the effect can add up.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When Effects Add Up or Cancel Out”, one chapter of our one-minute explainer. See how it works 

How to Manage the Molindone and Buprenorphine Interaction

Keep taking both medicines as prescribed unless your prescriber tells you otherwise. Your care team may prefer stopping the sedating medicine if possible, or may lower it gradually to the lowest effective dose. If you need both, they may monitor you more closely for sleepiness and slowed breathing, and may suggest other options for anxiety or sleep.

  • Tell your pharmacist and prescriber about all sedating medicines and alcohol you use.
  • Ask whether your doses may need to be adjusted and individualized.
  • Seek emergency help for extreme drowsiness, confusion, or slow or shallow breathing.

If you take buprenorphine for use disorder, you should not be denied it because of this interaction.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Molindone or Buprenorphine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

2 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks

    A Swedish epidemiological study reported that patients on methadone- or buprenorphine-based medication-assisted treatment (MAT) who also received or other depressants (for example, drugs used to treat insomnia) had an increased risk of death. For the period from July 1, 2005 to December 31, 2012, the investigators analyzed the risk of fatal overdose, non-overdose related mortality, and all-cause mortality in MAT patients (aged 18 to 50), comparing periods of prescribed CNS depressant use with periods without CNS depressant therapy.

    MAT combined with benzodiazepine treatment was associated with an elevated risk of all-cause mortality (adjusted hazard ratio (HR) 1.44; 95% CI, 0.93 to 2.23) and non-overdose related mortality (HR 1.74; 95% CI 1.00 to 3.01), but these findings were not considered statistically significant. During periods of of MAT and non-benzodiazepines, the risk of fatal overdose, non-overdose mortality, and all-cause mortality was elevated, yet only the fatal overdose and all-cause mortality results were considered statistically significant, with an HR of 2.34 (95% CI, 1.37 to 3.99) and an HR of 1.33 (95% CI, 1.12 to 2.45), respectively. The benzodiazepine and non-benzodiazepine cohorts were not compared with each other, because the authors did not adjust for the indication for which the drugs were used.1

  2. Report 2 · Study title

    Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks

    A study of aggregate nationwide death certificate data from 2010 to 2014 identified 3495 drug overdose deaths reported in 2014. Methadone and other depressants were often named as contributors to these deaths.

    Concurrent ALPRAZolam use was reported in 18.1% of cases, followed by oxyCODONE (10.1%), cocaine (9.6%), heroin (9%), and diazePAM (6.6%). The FDA reported 322 drug overdose deaths involving buprenorphine in 2014.

    Among these 322 deaths, 32.9% involved ALPRAZolam, 17.4% involved clonazePAM, 11.2% involved diazePAM, 11.2% involved heroin, and 9.9% involved fentaNYL. The absolute number of deaths involving methadone was 10 times that involving buprenorphine, although confounding factors and differences in drug utilization were not taken into account. Whether the risk of overdose death with CNS depressant drugs differed between buprenorphine and methadone is unknown.1

Molindone and Buprenorphine: Common Questions

How serious is the Molindone and Buprenorphine interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Molindone and Buprenorphine interaction managed?

Keep taking both medicines as prescribed unless your prescriber tells you otherwise. Your care team may prefer stopping the sedating medicine if possible, or may lower it gradually to the lowest effective dose. If you need both, they may monitor you more closely for sleepiness and slowed breathing, and may suggest other options for anxiety or sleep. Tell your pharmacist and prescriber about all se… Management is individual — always follow your own care team's guidance.

Is there an alternative to taking Molindone with Buprenorphine?

The interaction record says a different medicine may be considered in place of one of these two.

Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Molindone and Buprenorphine Interaction

Ask in your own words about taking Molindone and Buprenorphine together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (3)

  1. US Food and Drug Administration (FDA): Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration (FDA). Silver Spring, MD. 2017.
  2. Product Information: SUBUTEX(R) sublingual tablets, buprenorphine sublingual tablets. Indivior Inc (per FDA), North Chesterfield, VA, 2021. DailyMed
  3. Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
Was this write-up helpful?

Other Serious Interactions of Molindone and Buprenorphine

Also serious with Buprenorphine

Also serious with Molindone

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Buprenorphine

With Molindone

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.